NCI Drug Dictionary

The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.

Browse:
PE/HPV16 E7/KDEL fusion protein/GPI-0100 TVGV-1
A vaccine composed of a lyophilized fusion protein consisting of a peptide sequence of human papillomavirus type 16 (HPV16) E7 nuclear protein fused to the Pseudomonas aeruginosa exotoxin A (PE) and an endoplasmic reticulum (ER) retention signal (KDEL) combined with the immunoadjuvant GPI-0100, a semi-synthetic dodecylamide saponin derivative, with potential immunomodulating and antineoplastic activities. Upon administration of PE/HPV16 E7/KDEL fusion protein/GPI-0100 TVGV-1, the PE moiety of the fusion protein targets and binds to CD91 (Prolow-density lipoprotein receptor-related protein 1; LRP1) expressed on a variety of cells, including antigen-presenting cells (APCs) such as dendritic cells (DCs), which facilitates the internalization, through endocytosis, of TVGV-1. Following endocytosis, this agent is proteolytically cleaved by the proteasome and the epitopes from the HPV16 E7 protein become bound to major histocompatibility complex class I (MHC-I) molecules and are presented on the DC-cell surface. This facilitates a cytotoxic T-lymphocyte (CTL)-mediated immune response against HPV16 E7 expressing-tumor cells. KDEL targets the fusion protein to the ER which increases this agent's potential to be bound by MHC-I molecules and increases the immune response against HPV16 E7-expressing cancer cells. GPI-0100 acts as an adjuvant for vaccines to improve the immunogenicity of proteins. Check for active clinical trials using this agent. (NCI Thesaurus)

Synonym:PE-E7-KDEL/GPI-0100 TVGV-1
PEK fusion protein/GPI-0100 vaccine
TVGV-1 vaccine
Code name:TVGV-1